| Bioactivity | Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4]. |
| Invitro | 芬苯达唑d3 (20 µM; 48 小时) 逆转了 miR-143-5p 对增殖、集落形成能力和迁移的抑制作用[1]。芬苯达唑d3 (20 µM; 48 小时) 可以提高 HIF-1α 和 GLUT1 的蛋白质表达水平[1]。 Cell Proliferation Assay[1] Cell Line: |
| Name | Fenbendazole-d3 |
| CAS | 1228182-47-5 |
| Formula | C15H10D3N3O2S |
| Molar Mass | 302.37 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Jia Xu, et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway. Oncol Lett. 2022 May;23(5):147. [2]. Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8(1):11926. [3]. Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. [4]. Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb;33(2):355-62. |
Fenbendazole-d3
CAS: 1228182-47-5 F: C15H10D3N3O2S W: 302.37
Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-rela
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.